Legislación farmacéutica de la UE: El marco completo

La ley fundacional que regula los medicamentos de uso humano en la UE. Establece las normas para la autorización de comercialización, la fabricación, la distribución mayorista, la publicidad y la farmacovigilancia a través de procedimientos nacionales y descentralizados. Adoptada en 2001, consolidó y sustituyó directivas anteriores que se remontaban a 1965.

Establece la Agencia Europea de Medicamentos (EMA) y el procedimiento centralizado de autorización de comercialización. Una única solicitud ante la EMA resulta en una autorización válida en todos los Estados miembros de la UE/EEE. Obligatorio para productos biotecnológicos, medicamentos huérfanos y tratamientos para cáncer, VIH/SIDA, enfermedades neurodegenerativas, diabetes, enfermedades autoinmunes y virales.

Productos biotecnológicos, medicamentos huérfanos, VIH/SIDA, cáncer, enfermedades neurodegenerativas, diabetes, enfermedades autoinmunes, enfermedades virales y medicamentos de terapia avanzada (terapia génica, terapia celular somática, ingeniería tisular). Tiempo de evaluación: 210 días activos.

La base de datos de la UE de sospechas de reacciones adversas a medicamentos, gestionada por la EMA. Los titulares de autorización de comercialización deben notificar todas las sospechas de reacciones graves en un plazo de 15 días. Las herramientas clave incluyen los Informes Periódicos de Seguridad (PSUR), los Planes de Gestión de Riesgos (RMP) y el símbolo del triángulo negro para medicamentos bajo vigilancia adicional.

Sustituyó la Directiva 2001/20/CE sobre ensayos clínicos. Introduce el Sistema de Información sobre Ensayos Clínicos (CTIS): un portal único de la UE para todas las solicitudes de ensayos. Una solicitud puede cubrir varios Estados miembros, con una evaluación coordinada dirigida por un Estado miembro ponente. Los resultados de los ensayos deben publicarse en un plazo de 12 meses tras la finalización del estudio. Se aplican normas simplificadas a los ensayos clínicos de baja intervención.

Para enfermedades que afectan a no más de 5 de cada 10.000 personas en la UE. El Comité de Medicamentos Huérfanos de la EMA (COMP) concede la designación de huérfano. Los incentivos incluyen 10 años de exclusividad de mercado, asistencia en el protocolo y reducciones de tasas. Con la reforma de 2023, los huérfanos innovadores recibirán hasta 11 años.

Exige Planes de Investigación Pediátrica (PIP) para todos los medicamentos nuevos, evaluados por el Comité Pediátrico de la EMA (PDCO). Completar un PIP acordado otorga una prórroga de 6 meses del CCP. Se pueden conceder exenciones cuando la enfermedad no se da en niños o el producto no sería seguro.

Abarca la terapia génica, la terapia celular somática y los productos de ingeniería tisular. La autorización centralizada es obligatoria. El Comité de Terapias Avanzadas de la EMA (CAT) proporciona la evaluación científica. Estas terapias de vanguardia están transformando el tratamiento de enfermedades genéticas raras y cánceres.

Procedimiento simplificado de registro para medicamentos tradicionales a base de plantas con al menos 30 años de uso documentado (incluidos 15 años en la UE). El Comité de Medicamentos a Base de Plantas de la EMA (HMPC) prepara monografías que establecen perfiles de seguridad y eficacia.

Características de seguridad obligatorias en el envase: un identificador único (código de barras 2D) y un dispositivo contra la manipulación, verificados en la dispensación a través del Sistema Europeo de Verificación de Medicamentos (EMVS). Controles reforzados de la cadena de suministro para importadores, intermediarios y fabricantes de principios activos. Un logotipo común de la UE identifica las farmacias en línea legales.

El 26 de abril de 2023, la Comisión propuso sustituir tanto la Directiva (2001/83/CE) como el Reglamento (726/2004) por un marco modernizado. Tras cuatro triálogos, los negociadores alcanzaron un acuerdo provisional el 11 de diciembre de 2025. La reforma aborda los incentivos a la innovación, la resiliencia de la cadena de suministro, la resistencia antimicrobiana y el acceso de los pacientes.

For the first time in EU pharmaceutical law, the 2026 reform introduces regulatory sandboxes as a formal legislative tool. The European Commission, at the suggestion of the EMA, may establish a sandbox where a medicinal product cannot be developed and authorised under standard regulatory requirements due to its inherent scientific or technical characteristics.

Areas envisaged: personalised medicines, advanced therapy medicinal products (ATMPs), products incorporating artificial intelligence (AI) or digital health tools, and innovative antimicrobials such as phage therapy.

How it works: A controlled, supervised environment where targeted adaptations to current regulatory requirements are permitted. Lessons learned are converted into permanent regulatory rules that reflect scientific progress.

Interplay with AI Act: Companies developing AI-enabled medicinal products must navigate two separate sandbox frameworks: the pharma sandbox under the new regulation, and the AI Act sandbox regime (as strengthened by the Digital Omnibus proposal). These are distinct legal mechanisms with no formal cross-reference between them.

Pharmaceutical compounding refers to the preparation of customised medicines by pharmacies for individual patients. The 2026 Pharma Package clarifies the regulatory boundary between pharmacy compounding (which is exempt from marketing authorisation requirements under Article 3 of Directive 2001/83/EC) and industrial manufacturing.

Key clarifications in the reform:

• Compounding remains under national competence but must comply with Good Pharmacy Practice (GPP)
• Industrial-scale "compounding" that is not for a specific named patient triggers full GMP and marketing authorisation requirements
• The Falsified Medicines Directive (Dir 2011/62/EU) serialisation requirements apply to compounded products only when they enter the supply chain
• The reform does not harmonise compounding rules across Member States, leaving significant national variation (especially between common law and civil law jurisdictions)

Directive (EU) 2024/3019 (CELEX: 32024L3019), adopted 27 November 2024. This recast of the 1991 Urban Waste Water Treatment Directive is the most significant upgrade to EU water treatment rules in 33 years.

Why it matters for pharma:

• Extended Producer Responsibility (EPR): Pharmaceutical and cosmetic producers must finance quaternary treatment (advanced removal of micropollutants) at waste water treatment plants. This is a direct "polluter pays" mechanism: the industry that places micropollutants on the market pays for their removal
• Quaternary treatment: 80% removal of micropollutants (pharmaceuticals, PFAS) required for plants serving 150,000+ population equivalents by 2033, and 10,000+ p.e. by 2039
• EPR cost share: At least 80% of quaternary treatment costs borne by pharmaceutical and cosmetics producers, proportional to their micropollutant load
• Source: EPRS Briefing PE 740.240

Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals used in pharmaceutical manufacturing (coatings, packaging, equipment). The EU is pursuing the world's most comprehensive PFAS regulatory approach.

Cost of inaction: EUR 440 billion cumulative by 2050. EUR 1 trillion+ in water treatment costs without action. Sources: EC study (January 2026), DG ENV

Regulation (EC) 1907/2006 (REACH) is the EU's main chemicals legislation, enforced by ECHA in Helsinki. DG ENV overview.

Why it matters for pharma:

• Active ingredients: Pharmaceutical active substances are exempt from REACH registration when used in medicinal products (Article 2(5)(a)), but not when used as intermediates or in non-medicinal applications
• Excipients and process chemicals: All non-active chemical substances used in pharmaceutical manufacturing (solvents, excipients, cleaning agents) must be REACH-registered if produced/imported above 1 tonne/year
• SVHC authorisation: If a substance used in pharma manufacturing is added to the Authorisation List (Annex XIV), manufacturers must obtain authorisation for continued use or find substitutes
• REACH targeted revision (2023/0234(COD)): Proposes "One Substance, One Assessment" (OSOA) to streamline hazard assessment across ECHA, EFSA, EMA, and EEA. This directly impacts how pharma substances are evaluated
• Critical Medicines Act connection: The proposed CMA may create exemptions or fast-track procedures for substances essential to critical medicine manufacturing

Hospital and public health system pharmaceutical purchases are governed by the EU public procurement framework:

Key issues for pharma procurement: Joint procurement mechanisms (as used during COVID-19 for vaccines), Most Economically Advantageous Tender (MEAT) criteria allowing quality/innovation weighting over lowest price, and the International Procurement Instrument (Regulation 2022/1031) which can restrict third-country bidders in strategic sectors.

EU trade agreements directly affect pharmaceutical market access, IP protection, and regulatory cooperation:

The EU and the US are the world's two largest pharmaceutical markets. Their relationship is characterised by deep interdependency: European companies develop and manufacture globally, while the US market provides the highest prices and fastest regulatory approvals (FDA).

Key dynamics (2026):

• Tariff risk: US tariff policy under Trump II creates uncertainty for EU pharmaceutical exports. Pharma has historically been exempt from tariff disputes, but the current administration has signalled willingness to include it
• Regulatory divergence: The FDA and EMA are increasingly diverging on accelerated approval pathways, AI/digital health regulation, and biosimilar interchangeability rules. The EU's regulatory sandbox (new in the 2026 reform) has no US equivalent in the same form
• GMP mutual recognition: The EU-US Mutual Recognition Agreement on GMP inspections (fully operational since 2019) reduces duplicative inspections. This is the most successful transatlantic pharma cooperation mechanism
• China factor: Both the EU and US are seeking to reduce dependency on Chinese API (active pharmaceutical ingredient) manufacturing. The EU's proposed Critical Medicines Act and the US BIOSECURE Act both aim to reshore production
• Drug pricing: The US Inflation Reduction Act (IRA) introduced Medicare drug price negotiation for the first time, narrowing the EU-US price gap for selected medicines. This affects European companies' global pricing strategies